Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Dostarlimab |
Trade Name | |
Synonyms | TSR-042 |
Drug Descriptions |
Dostarlimab (TSR-042) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (Eur J Cancer 2016 Dec; 69 (Suppl 1):S102, Abstract # 310, PMID: 31847708, PMID: 32213091). |
DrugClasses | Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68 |
CAS Registry Number | 2022215-59-2 |
NCIT ID | C126799 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Dostarlimab + Niraparib | Bevacizumab Dostarlimab Niraparib | 0 | 1 |
Capecitabine + Dostarlimab | Capecitabine Dostarlimab | 0 | 1 |
Carboplatin + Dostarlimab + Paclitaxel | Carboplatin Dostarlimab Paclitaxel | 0 | 2 |
Docetaxel + Dostarlimab | Docetaxel Dostarlimab | 0 | 1 |
Docetaxel + Dostarlimab + TSR-022 | Docetaxel Dostarlimab TSR-022 | 0 | 1 |
Dostarlimab | Dostarlimab | 1 | 4 |
Dostarlimab + Fluorouracil | Dostarlimab Fluorouracil | 0 | 1 |
Dostarlimab + GSK6097608 | Dostarlimab GSK6097608 | 0 | 1 |
Dostarlimab + Niraparib | Dostarlimab Niraparib | 0 | 11 |
Dostarlimab + TSR-022 | Dostarlimab TSR-022 | 0 | 2 |
Dostarlimab + TSR-033 | Dostarlimab TSR-033 | 1 | 0 |